Hormonal
HIIT significantly improves lipid profiles (LDL, Triglycerides, Total Cholesterol) and insulin resistance (HOMA-IR) in patients with diabesity.
Focus on improving your insulin sensitivity and cholesterol through HIIT. This type of training has been shown to significantly lower your HOMA-IR score and improve LDL and Triglyceride levels compared to doing nothing, offering a powerful metabolic boost for those with diabesity.
fasting insulin (SMD -0.79 mIU/L...), homeostatic model assessment for insulin resistance (SMD -0.95...), low-density lipoprotein cholesterol (SMD -0.64 mg/dL...), triglycerides (SMD -0.64 mg/dL...), and total cholesterol (SMD -0.66 mg/dL...) improved compared to standard treatment without exercise.
Why this rating
Certainty of evidence for lipid outcomes is rated 'Very Low' due to risk of bias and inconsistency.
Source
Impact of high-intensity interval training on cardiometabolic health in patients with diabesity: a systematic review and meta-analysis of randomized controlled trials
Sameer Badri Al-Mhanna et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01974-4
More from this paper
- High-intensity interval training (HIIT) significantly improves cardiometabolic health markers—including glycemic control, insulin resistance, and lipid profiles—in patients with diabesity (Type 2 Diabetes and Obesity), even when body composition changes are minimal.Limited
- HIIT does not significantly improve body mass or BMI in patients with diabesity compared to standard treatment.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →